| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e395dd146c5e45421ca5a553e8b9b57 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f44b27fdc6363f04618b89010f8e0ea7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f158f939e812cca851771be8b4c3651 |
| publicationDate |
2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021009074-A1 |
| titleOfInvention |
Novel markers as early predictors of alzheimer's pathology |
| abstract |
The present invention generally relates to brain neuroscience field and relates to a new marker for evaluating cerebral beta-amyloid (Aβ) accumulation in the brain and methods for analysis thereof. In particular, the invention introduces a marker to be used in pre-symptomatic diagnosis, in clinical trial enrichment settings, and evaluation of drug efficacy of therapeutic and prophylactic drugs in Alzheimer's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022197651-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023068173-A1 |
| priorityDate |
2019-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |